

17 July 2025

Update on recruitment for innovative mental health trial in veterans

Highlights:

- Recruitment progressing well for clinical trial evaluating TrivarX's single-lead ECG screening technology for detecting current major depressive episodes (cMDE) in veterans
- A total of 10 patients have been enrolled and completed trial procedures
- Marks strong progress since recruitment began in June, and TrivarX remains on track to achieve its target of up to 30 patients
- Successful recruitment and collaboration highlight a strong partnership between TrivarX and its development partners, the Greater Los Angeles Veterans Research and Education Foundation (GLAVREF) and Veterans Affairs ('VA') Greater Los Angeles Healthcare System

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) is pleased to report that patient recruitment is advancing well in its clinical trial evaluating the Company's novel single-lead ECG algorithm to screen for current major depressive episodes (cMDE) in veterans with suspected sleep apnoea (*refer ASX Announcement 28 April 2025*).

The trial, underway at the West Los Angeles VA Medical Center, has now successfully enrolled 10 participants, all of whom have completed the required overnight polysomnography (PSG) sleep study and the Mini International Neuropsychiatric Interview (MINI) administered by qualified health professionals.

Since initiating patient recruitment in June (*refer ASX Announcement 19 June 2025*), the recruitment process has seen steady interest from veterans and the Company has received positive feedback from both patients and clinical staff. The study remains on track to achieve the target recruitment cohort of thirty patients, with completion anticipated by mid September.

The single-channel ECG algorithm is an extension of TrivarX's lead asset, MEB-001. The algorithm accurately performs sleep staging and detects cMDE in subjects using only heart rate (HR) and heart rate variability (HRV) metrics (*refer ASX Announcement 7 November 2024*).

Commentary:

Principal Investigator, Dr Jennifer Martin, commented: *"We are encouraged with the pace of enrolment and the high level of engagement from participating veterans. The study is proceeding according to protocol, and we remain confident in meeting our recruitment goals and advancing the trial to completion."*

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

ASX ANNOUNCEMENT



Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au